<DOC>
	<DOC>NCT01113346</DOC>
	<brief_summary>This is a phase II double blind multicenter randomized placebo-controled clinical study aimed to find out whether treatment with Filtrum-STI (orally administered 0,4g tablets) is safe and effective in children with viral gastroenteritis. Filtrum-STI (lignin hydrolytic) is a drug with a high absorbing ability, that binds and eliminates toxins, pathogenic microorganisms and viruses. Filtrum-STI is inoffensive for mucous membranes, enhances colonic propulsion and improves its natural microflora. The drug is not toxic and well combines with other medication</brief_summary>
	<brief_title>A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Adenovirus Infections, Human</mesh_term>
	<mesh_term>Enterovirus Infections</mesh_term>
	<criteria>children aged 04 y.o. diagnosed with moderate viral gastroenteritis; 72 h or less from the onset of gastrointestinal symptoms. severe diseases; individual intolerance of FiltrumSTI treatment with antiviral, immunomodulatory drugs during the study and 2 weeks before inclusion treatment with pre pro and antibiotics 2 weeks before inclusion participation in other clinical study 1 month before inclusion and during participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>enterosorbent</keyword>
	<keyword>sorbent</keyword>
	<keyword>gastrointestinal decontamination</keyword>
	<keyword>viral diarrhea</keyword>
	<keyword>rotavirus</keyword>
	<keyword>Filtrum</keyword>
	<keyword>Filtrum-STI</keyword>
	<keyword>lignin</keyword>
</DOC>